Clinical trials: Conversion Disorder, open to volunteers
Functional Neurological Disorder, Motor Symptoms
Investigating the Neurophysiology of the Motor System and the Feasibility of Vagus Nerve Stimulation in Functional Neurological Disorder (FND)
This clinical study will test if adding a non-invasive stimulation of the vagus nerve through the ear during physiotherapy brings an improvement to FND (Functional Neurological Disorder) patients with motor symptoms.
- Trial name
- TMS-VNS (NCT07710677)
- Testing
- Vagial Nerve Stimulation (VNS) active stimulation
- Where
- Switzerland
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Fribourg
REM Sleep Behavior Disorder
PREdictive Risk Factors of Conversion Into Idiopathic RBD. Italian Study
REM Sleep Behavior Disorder (RBD) is a REM sleep parasomnia first described in 1986 and characterized by the loss of physiological muscle atonia typical of REM sleep and by the presence of abnormal, sometimes violent, motor…
- Trial name
- FARPRESTO (NCT05262543)
- Where
- 2 sites in Italy
- Volunteers
- 300 people
- Sponsor
- University of Cagliari
Hepatocellular Carcinoma
Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Some people with HCC have no visible active tumor on imaging after receiving anticancer treatment.
- Trial name
- SWITCH-R (NCT07866612)
- Testing
- Curative-Intent Liver Resection, Immunotherapy-Based Systemic Maintenance Therapy
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Gastric Adenocarcinoma
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
To evaluate the efficacy and safety of Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1 conversion therapy for initial unresectable local progression or potential resectable metastatic gastric adenocarcinoma.
- Trial name
- NCT04047953
- Testing
- Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Peking University Cancer Hospital & Institute
Dissociative Disorder
Prevalence of Dissociative Identity Disorder in At-risk Outpatient Groups Reporting Childhood Trauma.
The investigators will study the prevalence of dissociative identity disorder (DID) in three populations at risk in cases of childhood psychotrauma : patients with a diagnosis of borderline personality, patients with a diagnosis…
- Trial name
- IDENTITY (NCT06330467)
- Testing
- psychometric assessment, semi-structured clinical interview
- Where
- 3 sites in France
- Volunteers
- 350 people
- Sponsor
- Centre Psychothérapique de Nancy
Ischemic Stroke
Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)
EXCELLENT was a prospective, multicenter, randomized, double-blind, placebo-controlled clinical study in which participants were randomized participants were randomized (1:1) to receive either IV thrombolysis + edaravone or IV…
- Trial name
- EXCELLENT (NCT07119021)
- Testing
- Intravenous thrombolysis + edaravone
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ruijun Ji
MCI, MCI Conversion to Dementia
Neurocognitive Assessment Platform 4 Alzheimer
The aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050.
- Conditions
- MCI, MCI Conversion to Dementia, AMCI - Amnestic Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NAP4A2020 (NCT07272811)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
This is a Phase II, open-label, single-arm, multicenter study evaluating the safety and efficacy of combining Tislelizumab with induction chemoradiotherapy (CRT), followed by conversion surgery, in patients with locally advanced…
- Trial name
- NCT07039162
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 8 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Ming-Yu Lien
Urinary Bladder Sphincter Disorder
Study of Bladder-sphincter Symptoms in Functional Neurological Disorders
A significant proportion of patients with functional neurological disorders (FND) report urinary, anorectal or genitosexual disorders. However, until now, no study has focused on bladder-sphincter disorders in patients with FND.
- Trial name
- URO-TNF (NCT05689866)
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Functional Movement Disorder
Passive Thoughts in Functional Movement Disorders
Passive thoughts also known as mind-wandering are the thoughts that are not produced from the current task. When we aren't focused on a task that needs our full attention, our minds tend to drift from one thought to another.
- Trial name
- NCT06439017
- Testing
- Questionaire
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Western University, Canada
PTSD - Post Traumatic Stress Disorder, Depression Disorders
Empowering Narratives
Background: The Russian invasion of Ukraine has resulted in forced displacement, with over 80,000 Ukrainian refugees now residing in Norway.
- Conditions
- PTSD - Post Traumatic Stress Disorder, Depression Disorders, Dissociation, Refugee
- Trial name
- EN (NCT07062042)
- Testing
- Narrative Exposure Therapy
- Where
- Norway
- Volunteers
- 50 people
- Sponsor
- Kristiania University College
Colo-rectal Cancer
FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.
This study is a single-center, prospective, randomized, single-arm phase II clinical trial designed to evaluate the safety and efficacy of FULIRI chemotherapy regimen combined with targeted therapy (bevacizumab/cetuximab) as…
- Trial name
- NCT07515963
- Testing
- FULIRI combination targeted therapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhongnan Hospital
Myopia (Disorder), Anisometropia
Children Receiving Monocular MiSight® 1 Day Treatment for Unilateral Myopia
This investigator-initiated prospective observational cohort study aims to establish the first longitudinal clinical database evaluating fellow-eye myopia development in children receiving monocular MiSight® 1 Day treatment for…
- Trial name
- NCT07778264
- Testing
- MiSight® 1 Day
- Volunteers
- 100 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Colon Cancer
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
The goal of this clinical trial is to evaluate the efficacy and safety of conversion therapy using radiotherapy combined with systemic treatment (chemotherapy + immune checkpoint inhibitors) for patients with pMMR/MSS T4M0 stage…
- Trial name
- NCT06949111
- Testing
- radiotherapy, CAPOX, Capecitabine
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Hebei Medical University Fourth Hospital
Functional Neurological Symptom Disorder, Functional Seizures
Accelerated TMS for Seizure-Type Functional Neurologic Disorders
The purpose of this project is to assess the feasibility, tolerability, and preliminary efficacy of using an accelerated, intermittent theta burst stimulation (a-iTBS-rTMS) protocol targeting the left dorsolateral prefrontal…
- Trial name
- FND-seiz (NCT07059325)
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical University of South Carolina
Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS)
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
To evaluate the efficacy and safety of immune checkpoint inhibitor-based combination therapy with targeted therapy and chemotherapy in patients with locally advanced unresectable or metastatic colorectal cancer.
- Trial name
- NCT07446465
- Testing
- Serplulimab, Fruquintinib, mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Ye Xu
Hepatocellular Carcinoma
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
This multicenter retrospective study which included patients with hepatocellular carcinoma (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options and the best benefit group.
- Trial name
- NCT06405321
- Testing
- Conversion or neoadjuvant therapy.
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma, SBRT
SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma
This is a Phase II , Open-label , Investigator-initiated Trail of SBRT in Combination With Adbelimumab and Apatinib in Patients With Hepatocellular Carcinoma(HCC).This study aims to evaluate the safety and efficacy of SBRT in…
- Conditions
- Hepatocellular Carcinoma, SBRT, Immune Checkpoint Blockade, Tyrosine Kinase Inhibitor
- Trial name
- NCT06538935
- Testing
- adbelimumab, SBRT, apatinib
- Volunteers
- 80 people
- Sponsor
- Fujian Cancer Hospital
Hepatocellular Carcinoma
Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent…
- Trial name
- NCT06382103
- Testing
- ctDNA monitoring, Plasma proteomic analysis
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Shanghai Zhongshan Hospital
Colon Cancer, Synchronous Liver Metastases
QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study
This is a single-arm clinical study aiming to enroll 30 colon cancer patients with liver-only metastases. All eligible participants will undergo screening and enrollment after signing the informed consent form.
- Trial name
- NCT07649473
- Testing
- QL1706 (Iparomlimab/Tuvonralimab)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fujian Medical University